Proximal Tumors Are Associated with Greater Mortality in Colon Cancer
Colon cancer is the third leading cause of death from cancer in the United States. Recent studies report on increasing proportions of proximal cancers. The etiology behind this epidemiological trend is unclear, and its implication on survival outcomes is unknown. Further analysis of the impact of anatomic site of disease among a large multiethnic population will help facilitate research and education to improve colon cancer screening and treatment.
To investigate the association between proximal tumor location and survival in patients with colon cancer.
DESIGN AND PARTICIPANTS
A large retrospective cohort study in the US utilizing the Surveillance, Epidemiology, and End Results (SEER) cancer registry analyzed survival outcomes of patients with colon cancer. Multivariable logistic regression analyses investigated sex-specific, race/ethnicity-specific, and anatomic site-specific disparities in survival.
Five-year survival outcomes from colon cancer.
Our study demonstrated significant disparities in survival by sex, race/ethnicity, and anatomic site. Across all time periods and among most cohorts, patients with proximal cancers had significantly worse survival outcomes. When compared to distal cancers, patients with proximal cancers were 13% less likely to survive 5 years (OR 0.87; 95% CI, 0.82–0.91). When compared to non-Hispanic whites, blacks were 30% less likely to survive 5 years (OR 0.70; 95% CI, 0.68–0.73). Stage-specific multivariable regression analysis of localized cancers demonstrated similar findings.
Significant race-specific, sex-specific, and anatomic site-specific disparities in colon cancer survival exist. Proximal cancers are associated with worse survival odds. These disparities may reflect differences in the genotype and phenotype of colon cancer among these groups. A modified risk assessment tool that incorporates these variations may be more effective in the early detection and treatment of colon cancer.
KEY WORDScolorectal cancer cancer screening epidemiology
- 1.American Cancer Society. Cancer Facts and Figures 2009. Atlanta: American Cancer Soc; 2009. Accessed at http://www.cancer.org/Research/CancerFactsFigures/index on July 3, 2010.
- 2.Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. American Cancer Society Colorectal Cancer Advisory Group. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.CrossRefPubMedGoogle Scholar
- 11.Wong RJ. Marked variations in colon cancer epidemiology: sex-specific and race/ethnicity-specific disparities. Gastroenterol Res. 2009;5:268–76.Google Scholar
- 19.Ries LAG, Melbert D, Krapcho M, et al., eds. SEER cancer statistics review, 1975–2005. Bethesda, MD: National Cancer Institute; 2008.Google Scholar
- 20.Surveillance, Epidemiology, and End Results (SEER) Program Public Use CD-ROM. (1973-2005). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008.Google Scholar
- 21.World Health Organization. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.Google Scholar
- 22.Young JL, Roffers SD, Ries LAG, et al., eds. SEER Summary Staging Manual–2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001.Google Scholar
- 23.Silva IS. Cancer Epidemiology: Principles and Methods. Geneva, Switzerland: World Health Organization; 2001.Google Scholar
- 30.Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labranci R, Hamilton SR. Defective mismatch repair as a predictive marker for lack of efficacy of Fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 [E-pub ahead of print] PMID:20498393.Google Scholar
- 33.The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;228:2891–97.Google Scholar
- 34.Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in black patients. Q J Med. 1999;92:187–92.Google Scholar
- 36.Wong RJ. Marked Variations in Proximal Colon Cancer Survival by Race/Ethnicity Within the United States. J Clin Gastroenterol. 2009 [Epub ahead of print] PMID: 19996985Google Scholar